Alexion has routinely featured ... and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and-stock takeover offer. The deal – the largest in the pharma sector ...

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 ...

Alexion, AstraZeneca Rare Disease, and DHL Express announced a partnership to reduce greenhouse gas emissions (GHG) from the ...

AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...

In May 2024, plans were cheerfully announced for a £450m facility to be built in Speke, Liverpool, where the pharmaceutical company AstraZeneca ... “fumbled” the deal. From the current ...

While Sir Keir Starmer’s party initially put forward only £40m of public money available for the deal, it was eventually raised to £78m - but AstraZeneca, claiming reasons beyond the funding ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

In May 2024, plans were cheerfully announced for a £450m facility to be built in Speke, Liverpool, where the pharmaceutical company AstraZeneca would be manufacturing ... saying Labour had “fumbled” ...

Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information ...